Novavax (NVAX) stock Forecast for 2022 – 2026
Last update: 05-28-2022, 12:20
Sector: HealthcareThe share price of Novavax, Inc. (NVAX) now
What analysts predict:: $158.67
52-week high/low: $277.8 / $41.33
50/200 Day Moving Average: $61.76 / $138.18
This figure corresponds to the average price over the previous 50/200 days. For Novavax stocks, the 50-day moving average is the resistance level today.
For Novavax stocks, the 200-day moving average is the resistance level today.
Are you interested in Novavax, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Novavax stock price in 2022, 2023, 2024, 2025, 2026. How much will one Novavax share be worth in 2022 - 2026?
When should I take profit in Novavax stock? When should I record a loss on Novavax stock? What are analysts' forecasts for Novavax stock? What is the future of Novavax stock?
We forecast Novavax stock performance using neural networks based on historical data on Novavax stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Novavax stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2022, 2023, 2024, 2025 and 2026)
The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Novavax shares. This happens once a day.
Historical and forecast chart of Novavax stock
The chart below shows the historical price of Novavax stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Novavax stock price can be found in the table below.
Long-term forecasts by years.
Novavax daily forecast for a month
| Date | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| May 30 | 59.54 | 57.88 | 63.78 | 10.18 |
| May 31 | 60.46 | 56.10 | 62.58 | 11.54 |
| Jun 01 | 58.17 | 56.50 | 60.21 | 6.58 |
| Jun 02 | 60.16 | 57.56 | 63.08 | 9.59 |
| Jun 03 | 64.33 | 61.43 | 66.99 | 9.05 |
| Jun 04 | 63.92 | 60.76 | 67.95 | 11.84 |
| Jun 05 | 63.52 | 60.72 | 64.84 | 6.78 |
| Jun 06 | 62.78 | 58.99 | 63.91 | 8.33 |
| Jun 07 | 58.88 | 55.81 | 61.00 | 9.31 |
| Jun 08 | 59.36 | 56.31 | 62.51 | 11.00 |
| Jun 09 | 61.49 | 58.67 | 63.49 | 8.21 |
| Jun 10 | 63.21 | 59.28 | 65.94 | 11.23 |
| Jun 11 | 65.26 | 63.85 | 66.84 | 4.69 |
| Jun 12 | 70.25 | 65.57 | 74.74 | 13.98 |
| Jun 13 | 68.29 | 63.56 | 71.48 | 12.47 |
| Jun 14 | 66.63 | 63.51 | 69.63 | 9.63 |
| Jun 15 | 72.33 | 69.66 | 75.13 | 7.85 |
| Jun 16 | 73.50 | 70.92 | 76.81 | 8.30 |
| Jun 17 | 75.48 | 70.32 | 79.97 | 13.72 |
| Jun 18 | 77.59 | 72.14 | 80.87 | 12.10 |
| Jun 19 | 74.79 | 71.23 | 77.62 | 8.98 |
| Jun 20 | 72.37 | 70.87 | 77.13 | 8.82 |
| Jun 21 | 76.02 | 72.32 | 79.30 | 9.65 |
| Jun 22 | 79.17 | 75.89 | 82.94 | 9.29 |
| Jun 23 | 78.67 | 73.43 | 81.50 | 10.99 |
| Jun 24 | 77.32 | 74.96 | 82.47 | 10.03 |
| Jun 25 | 73.08 | 71.56 | 74.98 | 4.78 |
| Jun 26 | 71.30 | 68.54 | 74.25 | 8.33 |
| Jun 27 | 70.92 | 68.75 | 73.60 | 7.06 |
| Jun 28 | 67.98 | 63.88 | 71.65 | 12.16 |
Novavax Daily Price Targets
Novavax Stock Forecast 05-30-2022.
Pessimistic target level: 57.88
Optimistic target level: 63.78
Novavax Stock Forecast 05-31-2022.
Pessimistic target level: 56.10
Optimistic target level: 62.58
Novavax Stock Forecast 06-01-2022.
Pessimistic target level: 56.50
Optimistic target level: 60.21
Novavax Stock Forecast 06-02-2022.
Pessimistic target level: 57.56
Optimistic target level: 63.08
Novavax Stock Forecast 06-03-2022.
Pessimistic target level: 61.43
Optimistic target level: 66.99
Novavax Stock Forecast 06-04-2022.
Pessimistic target level: 60.76
Optimistic target level: 67.95
NVAX (NVAX) Monthly Stock Prediction for 2022
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jun. | 51.39 | 48.15 | 54.78 | 12.10 |
| Jul. | 50.00 | 43.55 | 60.35 | 27.84 |
| Aug. | 44.00 | 40.44 | 52.19 | 22.51 |
| Sep. | 33.57 | 29.34 | 40.22 | 27.05 |
| Oct. | 32.57 | 29.34 | 36.77 | 20.19 |
| Nov. | 35.69 | 32.80 | 43.62 | 24.80 |
| Dec. | 36.76 | 29.59 | 43.49 | 31.95 |
Novavax forecast for this year
Novavax Stock Prediction for Jun 2022
An downtrend is forecast for this month with an optimal target price of $51.3888. Pessimistic: $48.15. Optimistic: $54.78
Novavax Stock Prediction for Jul 2022
An downtrend is forecast for this month with an optimal target price of $50.0013. Pessimistic: $43.55. Optimistic: $60.35
Novavax Stock Prediction for Aug 2022
An downtrend is forecast for this month with an optimal target price of $44.0012. Pessimistic: $40.44. Optimistic: $52.19
Novavax Stock Prediction for Sep 2022
An downtrend is forecast for this month with an optimal target price of $33.5729. Pessimistic: $29.34. Optimistic: $40.22
Novavax Stock Prediction for Oct 2022
An downtrend is forecast for this month with an optimal target price of $32.5657. Pessimistic: $29.34. Optimistic: $36.77
Novavax Stock Prediction for Nov 2022
An uptrend is forecast for this month with an optimal target price of $35.692. Pessimistic: $32.80. Optimistic: $43.62
Novavax Stock Prediction for Dec 2022
An uptrend is forecast for this month with an optimal target price of $36.7628. Pessimistic: $29.59. Optimistic: $43.49
Novavax (NVAX) Monthly Stock Prediction for 2023
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 34.01 | 26.25 | 36.66 | 28.39 |
| Feb | 31.76 | 24.61 | 38.62 | 36.27 |
| Mar | 36.81 | 32.06 | 41.67 | 23.06 |
| Apr | 33.50 | 30.08 | 39.53 | 23.90 |
| May | 38.32 | 33.84 | 46.71 | 27.56 |
| Jun | 47.40 | 43.00 | 52.81 | 18.58 |
| Jul | 43.85 | 38.72 | 53.19 | 27.21 |
| Aug | 54.24 | 41.71 | 66.93 | 37.68 |
| Sep | 60.26 | 53.21 | 71.29 | 25.36 |
| Oct | 53.21 | 41.40 | 62.31 | 33.56 |
| Nov | 52.41 | 45.18 | 57.92 | 21.99 |
| Dec | 49.74 | 43.92 | 53.17 | 17.40 |
Novavax (NVAX) Monthly Stock Prediction for 2024
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 37.80 | 30.66 | 41.66 | 26.41 |
| Feb | 30.09 | 24.22 | 35.87 | 32.47 |
| Mar | 27.02 | 24.35 | 32.61 | 25.35 |
| Apr | 22.40 | 18.97 | 25.36 | 25.18 |
| May | 20.32 | 17.51 | 24.95 | 29.80 |
| Jun | 18.55 | 15.43 | 22.67 | 31.92 |
| Jul | 16.60 | 14.66 | 17.65 | 16.93 |
| Aug | 20.49 | 18.21 | 21.84 | 16.60 |
| Sep | 18.95 | 15.43 | 22.99 | 32.89 |
| Oct | 16.85 | 15.28 | 18.87 | 19.02 |
| Nov | 17.10 | 15.71 | 18.28 | 14.03 |
| Dec | 15.20 | 12.15 | 16.11 | 24.62 |
Novavax (NVAX) Monthly Stock Prediction for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 13.20 | 12.25 | 15.29 | 19.93 |
| Feb | 15.61 | 13.50 | 16.69 | 19.08 |
| Mar | 19.54 | 16.14 | 22.65 | 28.73 |
| Apr | 17.96 | 14.24 | 20.39 | 30.13 |
| May | 21.46 | 18.05 | 25.78 | 29.97 |
| Jun | 20.43 | 16.26 | 23.07 | 29.50 |
| Jul | 22.33 | 20.32 | 24.88 | 18.31 |
| Aug | 25.35 | 21.17 | 30.67 | 30.99 |
| Sep | 23.75 | 18.76 | 27.24 | 31.12 |
| Oct | 18.41 | 15.15 | 19.90 | 23.87 |
| Nov | 15.81 | 13.53 | 16.90 | 19.92 |
| Dec | 14.82 | 12.50 | 18.06 | 30.76 |
Novavax (NVAX) Monthly Stock Prediction for 2026
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 15.57 | 13.38 | 16.60 | 19.42 |
| Feb | 19.82 | 18.34 | 22.50 | 18.50 |
| Mar | 18.81 | 16.05 | 20.90 | 23.22 |
| Apr | 24.28 | 19.48 | 25.74 | 24.34 |
| May | 30.26 | 25.27 | 34.53 | 26.82 |
| Jun | 35.25 | 30.28 | 43.61 | 30.56 |
| Jul | 35.25 | 26.90 | 42.65 | 36.94 |
| Aug | 33.77 | 26.38 | 37.01 | 28.74 |
| Sep | 30.33 | 27.51 | 37.06 | 25.78 |
| Oct | 33.42 | 29.21 | 39.44 | 25.93 |
| Nov | 36.53 | 34.12 | 41.90 | 18.57 |
| Dec | 39.05 | 32.49 | 47.25 | 31.24 |
Novavax information and performance
Novavex, Inc. Together with its subsidiary Novavax AB, a late-stage biotechnology company, it discovers, develops and commercializes vaccines to prevent serious infectious diseases. The company’s leading vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate, which is in stage III clinical trials to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in phase III clinical trials for the treatment of seasonal influenza in the elderly. Its leading adjuvant is Matrix-M, which is used to enable the vaccine to enhance the amplitude of the immune response and qualitatively change it, and to allow the immune system to attack microorganisms, and also to allow immunization with much smaller doses of antigen. The company is also developing the RSV F vaccine for the elderly (60 years and older), which is in phase II clinical trials, as well as for healthy children aged six months to five years, who are in phase I clinical trials. In addition, it is developing candidate nanoparticle vaccines for clinical trials against the Ebola virus, which is in clinical trials stage I; and a combined respiratory vaccine to protect against influenza and RSV. In addition, the company is developing a COVID-19 vaccine against the pneumonia-like coronavirus, which is in the preclinical stage. Novavex, Inc. the company was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax Address
20 FIRSTFIELD ROAD, GAITHERSBURG, MD, US
Market Capitalization: 4 016 119 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: -157 414 000 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: None
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: N/A
Price/earnings to growth
DPS: N/A
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
DY: N/A
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS: -17.51
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: 0.574
Trailing PE: -
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: 1.502
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: 1.68
Enterprise Value (EV) /Revenue
EV To EBITDA: -
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 78135000
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A
Novavax (NVAX) stock dividend
Novavax last paid dividends on 01/01/1970. The next scheduled payment will be on 05/10/2019. The amount of dividends is $0 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Factor:
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.